Unicycive Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Unicycive Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 97% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 96% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 1,352% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 91% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-723.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 97% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / +1644%In 3 years sales changed by -100% while total assets changed by +1644%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-381.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 96% of Healthcare companies in United States.
Cash Cushion Ratio
+38%Cash, after subtracting all debt, equals 38% of its market value (net cash).
Higher than 73% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Unicycive Therapeutics, Inc. made a loss over the last year. Unicycive Therapeutics, Inc. owes $0.26 for every $1 it owns. Unicycive Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossUnicycive Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.03The share price is 2.03 times Unicycive Therapeutics, Inc.'s book value per share, lower than 59% of Healthcare companies in United States.
Market cap
$108 MThe total market value of all of Unicycive Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 64% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$53 MWhat Unicycive Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.94Net worth divided by the number of shares. The share price of $3.94 is 2.0 times this, which is the P/B above.
Return on equity (ROE)
-101.1%Unicycive Therapeutics, Inc. lost 101.1% of its shareholders' money over the last year, lower than 71% of Healthcare companies in United States.
Owes vs Owns
0.26×Unicycive Therapeutics, Inc. owes $0.26 for every $1 it owns (low), lower than 65% of Healthcare companies in United States.
Dividend yield
NoneUnicycive Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossUnicycive Therapeutics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredUnicycive Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashUnicycive Therapeutics, Inc. held $41 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Unicycive Therapeutics, Inc.: $108 M ÷ $53 M (30 Jun 2026) = 2.0.
What is Unicycive Therapeutics, Inc.'s return on equity?
Unicycive Therapeutics, Inc. lost 101.1% of its shareholders' money over the last year, lower than 71% of Healthcare companies in United States.
How much does Unicycive Therapeutics, Inc. owe compared with what it owns?
Unicycive Therapeutics, Inc. owes $0.26 for every $1 it owns (low), lower than 65% of Healthcare companies in United States.
Does Unicycive Therapeutics, Inc. pay a dividend?
No. Unicycive Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.